Cephalalgia 2022 Sep 8;3331024221123058. doi: 10.1177/03331024221123058. Online ahead of print. Michel Lanteri-Minet, Anne Ducros , Clement Francois, Elzbieta Olewinska, Mateusz Nikodem, Laure Dupont-Benjamin Abstract Background: This meta-analysis evaluated the real-world effectiveness of onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for chronic migraine in 2010.
Treatment of Chronic Refractory Pain by Combined Deep Brain Stimulation of the Anterior Cingulum and Sensory Thalamus (EMOPAIN Study): Rationale and Protocol of a Feasibility and Safety Study
Brain sciences 2022 Aug 23;12(9):1116. Aurélie Leplus, Michel Lanteri-Minet, Anne Donnet, Nelly Darmon, Jean Regis, Denys Fontaine Abstract Background: Deep Brain Stimulation (DBS) of the sensory thalamus has been proposed for 40 years to treat medically refractory neuropathic pain, but its efficacy remains partial and
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
The Lancet Neurology 2022 Jul;21(7):597-607 doi: 10.1016/S1474-4422(22)00185-5. Messoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling Abstract Background: The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and
Occipital Nerve Stimulation for Recurrent Trigeminal Neuralgia Without Occipital Pain
Neuromodulation : Journal of the International Neuromodulation Society 2022 Jun 7;S1094-7159(22)00649-3. doi: 10.1016/j.neurom.2022.03.012. Online ahead of print. Anne Balossier, Anne Donnet, Jean Régis, Aurélie Leplus , Michel Lantéri-Minet, Denys Fontaine Abstract Objectives: Trigeminal neuralgia (TN) is a severe, debilitating pain condition causing physical and emotional
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
The journal of headache and pain 2022 May 3;23(1):53 doi: 10.1186/s10194-022-01424-w. Alexandre O Gérard, Diane Merino, Elise K Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet, Milou-Daniel Drici Abstract Background: Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide
Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies
Current Medical Research and Opinion 2022 May 13;1-18 doi: 10.1080/03007995.2022.2076475. Online ahead of print. Serge Perrot, Alain Eschalier, Jules Desmeules, Michel Lanteri-Minet, Nadine Attal Abstract Background: Paracetamol is the commonest analgesic worldwide in primary care. Despite evidence-based recommendations for management of acute and chronic
Artificial intelligence to evaluate postoperative pain based on facial expression recognition
European Journal of Pain 2022 Mar 30 doi: 10.1002/ejp.1948. Online ahead of print. Denys Fontaine, Valentin Vielzeuf, Philippe Genestier, Pascal Limeux, Serena Santucci-Sivilotto, Emmanuel Mory, Nelly Darmon, Michel Lanteri-Minet, May Mokhtar, Melanie Laine, Damien Vistoli, DEFI study group Abstract Background: Pain intensity evaluation by self-report is difficult and biased in
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study
Journal of Neurology, Neurosurgery and Psychiatry 2022 March 09;jnnp-2021-327480 Michel Dominique Ferrari, Uwe Reuter, Peter J Goadsby , Gabriel Paiva da Silva Lima, Subhayan Monda, Shihua Wen, Nadia Tenenbaum, Shaloo Pandhi, Michel Lanteri-Minet, Tracy Stites Abstract Objective: To evaluate individual
Ketamine in chronic pain: A Delphi survey
European Journal of Pain 2022 Jan 29 doi: 10.1002/ejp.1914 Marion Voute, Thibault Riant, Jean-Marie Amodéo, Gilbert André, Mario Barmaki, Olivier Collard, Caroline Colomb, Christelle Créac’h, Rodrigue Deleens, Claire Delorme, Géraldine de Montgazon, Véronique Dixneuf, Lénaïg Dy , Jacques Gaillard , Christian Gov , Xavier Kieffer, Michel Lanteri-Minet, Jean-Marie Le Borgne, Franck Le Caër, Fadel Maamar, Caroline Maindet, Fabienne Marcaillou, Frédéric Plantevin, Yves-Marie Pluchon, Bruno
Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 3: Non-pharmacological treatment
Revue Neurologique 2021 Sep;177(7):753-759 G Demarquay, J Mawet, E Guégan-Massardier, S de Gaalon, A Donnet, P Giraud, M Lantéri-Minet, C Lucas, X Moisset, C Roos, D Valade, A Ducros Abstract The French Headache Society proposes updated French guidelines for the